CORT - Corcept Therapeutics...About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $13.45 | Open | $13.34 |
| Volume | 947.5K | Market Cap | 1.149B |
| Yield | Last Dividend |
| The Daily Biotech Pulse: MediciNova On T... | 06/24/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) ACA... | |
| Why Is Corcept (CORT) Up 8.2% Since Last... | 06/03/20 |
| Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | |
| Has Corcept Therapeutics (CORT) Outpaced... | 06/03/20 |
| Is (CORT) Outperforming Other Medical Stocks This Year? | |
| Corcept (CORT) Q1 Earnings Top Estimates... | 05/05/20 |
| Corcept's (CORT) earnings and revenues beat estimates in the first quarter of 2020. Solid adoption of the company's Cushing's syndrome drug, Korlym, d... | |
| Corcept Therapeutics (CORT) Tops Q1 Earn... | 05/04/20 |
| Corcept (CORT) delivered earnings and revenue surprises of 19.05% and 7.35%, respectively, for the quarter ended March 2020. Do the numbers hold clues... | |
| The Week Ahead In Biotech: Smid-Cap Earn... | 05/03/20 |
| Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma nam... | |
| Cushing's Syndrome Pipeline Insight, 202... | 05/01/20 |
| DUBLIN--(BUSINESS WIRE)--The "Cushing's Syndrome Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. This repo... | |
| Are You Looking for a Top Momentum Pick?... | 04/27/20 |
| Does Corcept Therapeutics (CORT) have what it takes to be a top stock pick for momentum investors? Let's find out. | |
| Corcept Therapeutics' Shares March Highe... | 04/13/20 |
| As of late, it has definitely been a great time to be an investor in Corcept Therapeutics. | |
| Why You Shouldn't Bet Against Corcept Th... | 04/02/20 |
| Corcept Therapeutics (CORT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well. | |
| Corcept (CORT) Down 24.9% Since Last Ear... | 03/21/20 |
| Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | |
| Shareholder Alert: Robbins LLP Is Invest... | 02/24/20 |
| SAN DIEGO & MENLO PARK, Calif.--(BUSINESS WIRE)---- $CORT #ClassAction--Shareholder rights law firm Robbins LLP is investigating the officers and dire... | |
| Corcept (CORT) Q4 Earnings In-Line with ... | 02/21/20 |
| Corcept Therapeutics (CORT) reports in-line earnings in the fourth quarter of 2020. | |
| Why Corcept (CORT) Could Beat Earnings E... | 02/19/20 |
| Corcept (CORT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat ... | |
| What's in Store for Corcept (CORT) This ... | 02/18/20 |
| During Corcept's (CORT) Q4 earnings call, investor focus will be on the sales uptake of its Cushing's syndrome drug Korlym and other pipeline updates. | |
| Corcept Therapeutics (CORT) to Report Q4... | 02/17/20 |
| Corcept (CORT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with t... | |
| Corcept Therapeutics reports preliminary... | 01/30/20 |
| Corcept Therapeutics (NASDAQ:CORT): Q4 Revenue of $87.9M (+31.6% Y/Y) in-line. Cash and investments of $315.3M Press Release | |
| Why Is Corcept (CORT) Down 8.9% Since La... | 12/07/19 |
| Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | |
| Corcept (CORT) Earnings Beat in Q3, Korl... | 11/08/19 |
| Corcept (CORT) rides high on both earnings and revenue beat in the third quarter. | |
| Corcept Therapeutics Incorporated : Anno... | 11/07/19 |
| PDF Version MENLO PARK, Calif., Nov. 07, 2019 -- Corcept Therapeutics Incorporated , a commercial-stage company engaged in the discovery and developme... | |
| Analysts Estimate Corcept Therapeutics (... | 10/31/19 |
| Corcept (CORT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with t... | |
| Why Corcept (CORT) is Poised to Beat Ear... | 10/14/19 |
| Corcept (CORT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat ... | |
| Corcept (CORT) Up 15.1% Since Last Earni... | 08/31/19 |
| Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | |
| Corcept Therapeutics (CORT) Q2 Earnings ... | 08/01/19 |
| Corcept (CORT) delivered earnings and revenue surprises of 38.89% and -0.34%, respectively, for the quarter ended June 2019. Do the numbers hold clues... | |
| Corcept (CORT) Down 11.3% Since Last Ear... | 06/08/19 |
| Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | |
| Corcept Therapeutics Incorporated (CORT)... | 05/10/19 |
| CORT earnings call for the period ending March 31, 2019. | |
| Corcept Therapeutics Inc. (CORT) CEO Jos... | 05/09/19 |
| Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2019 Results Earnings Conference Call May 09, 2019, 05:00 PM ET Company Participants Charlie Robb -... | |
| Corcept Therapeutics (CORT) Q1 Earnings ... | 05/09/19 |
| Corcept (CORT) delivered earnings and revenue surprises of 11.11% and -3.96%, respectively, for the quarter ended March 2019. Do the numbers hold clue... | |
| Corcept Therapeutics beats by $0.01, mis... | 05/09/19 |
| No summary available. | |
| Healthcare And Biotechnology Dashboard -... | 04/16/19 |
| No summary available. | |
| Hold rating | 08/05/20 |
| Jefferies downgrades from Buy to Hold rating and announces Price Target of $16.00 | |
| Date | 2020-08-04 (AMC) | Est. (EPS/Rev.) | $0.22/ 90.14M |
| Actual (EPS/Rev.) | $0.32/ $88.57 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
